AZD1390

Small molecule

Phase 1Undisclosed / early pipeline
Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
Glioblastoma
NCT03970447 · Global Coalition for Adaptive Research
2019-07-30 – 2030-06 · Glioblastoma
What this study did
Phase 1 (5)
Glioblastoma
NCT06894979 · Children's Oncology Group
2025-06-18 – 2028-03-31 · Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma, Childhood Glioblastoma, Childhood Malignant Glioma
What this study did
NCT05182905 · Nader Sanai
2022-05-27 – 2026-12-10 · Glioblastoma, Glioma, Glioblastoma Multiforme, Glioma, Malignant
What this study did
NCT03423628 · AstraZeneca
2018-04-02 – 2026-08-31 · Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
What this study did
Other / comorbidity
NCT07643870 · AstraZeneca
2026-06-30 – 2028-04-12 · Advanced Solid Malignancies
What this study did
NCT04550104 · University of Leeds
2021-03-17 – 2028-03 · Non Small Cell Lung Cancer
What this study did

Competitive landscape

This drug's own stage for Glioblastoma: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
AZD1390: this drugPhase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
TemozolomideApprovedSmall moleculeDNA alkylation (O6-guanine)not yet gradedNo reviewed efficacy summary in this indication
NiraparibPhase 3Small moleculePARP1/2not yet gradedNo reviewed efficacy summary in this indication
TemferonPhase 1/2Gene therapy / editingInterferon-alpha2 (myeloid-specific expression), Interferon-alpha2 (IFN-alpha2) expression in myeloid cellsnot yet gradedNo reviewed efficacy summary in this indication
TNG456Phase 1/2Small moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication
ZedoresertibPhase 1/2Small moleculeWEE1 kinasenot yet gradedNo reviewed efficacy summary in this indication
RalometostatDiscontinuedSmall moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow AZD1390 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (3)
March 2028 (1)
Phase 1GlioblastomaActive not recruiting
Est. primary completion 2028-03-31 · NCT06894979 · CT.gov ↗
What to watch
April 2028 (1)
Phase 1Advanced Solid MalignanciesNot yet recruiting
Est. primary completion 2028-04-12 · NCT07643870 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2/3GlioblastomaRecruiting
Est. primary completion 2028-06 · NCT03970447 · CT.gov ↗
What to watch

See the full readout calendar ↗